At least one biotechnology company that develops new drugs for a living has created its own virtual reality platform for drug discovery. Founded in 2007, C4X Discovery (C4XD) out of Manchester, England, is a small-cap public company that has developed its own VR platform called 4Sight.
Dr Craig Fox, Chief Scientific Officer of C4X Discovery #C4XD discusses their collaboration with PhoreMost to accelerate Parkinson's Disease drug discovery pipeline.
(Interview starts at 10 minutes 15 seconds)
Chemists at C4X Discovery are using the virtual reality technology behind popular game Fortnite to visualize the structure of complex molecules. The tool, called 4Sight, has already been used to create a drug that is now in development to treat addiction.
For U.K.-based C4X Discovery Holdings PLC, gaming engines are powering a more efficient drug-discovery process. The company uses the engines to discover molecules that help fight diseases like Alzheimer’s, Parkinson’s and ulcerative colitis, then licenses the resulting drugs to customers.
UK-based Pharmaceutical research firm C4X Discovery recently starting using Unreal Engine technology to visualize and manipulate 3-D molecules in virtual reality, with the potential to let scientists collaborate remotely in the virtual environment.
...Take C4X, a drug discovery and development company that has a wholly-owned drug pipeline but is also developing molecules in partnership with pharma, biotech and academia.
Clive Dix, chief executive, says large pharmaceutical companies “are crying out for innovation and are struggling to get enough of it in their own organisation to have the best molecules coming through. They’re therefore going to . . . smaller, more innovative companies and licensing products from them”.
Its proprietary technologies include a tool that analyses genetic databases, and another that determines the 3D shape of drug molecules while they are still at the test-tube stage.
“Manchester based C4X Discovery celebrated the only double win on the night, achieving the Bionow Project of the Year award for the development of Orexin-1 Receptor Antagonists for the Treatment of Addiction, while its Lead Software Developer Phil Muwanga won in the prestigious Promising Technologist of the Year category. Phil is applying gaming technology and virtual reality to revolutionise the drug discovery industry allowing scientists to visualise how drugs interact with our bodies at the molecular level…"
Taking a patient-centered approach, Indivior is developing innovative treatments for addiction to opioids, alcohol, and stimulants, as well as accompanying illnesses such as schizophrenia.
...selective blockade of the OX1 receptor decreases drug seeking and prevents relapse or reinstatement of drug-seeking behavior during abstinence in animal models of addiction. Indivior has entered into a partnership with C4X Discovery to develop their lead molecule, C4X3256, a selective OX1 receptor antagonist.